Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KNLBT
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
KR1020250011922A ADC-TRA41C
|
|||||
| Synonyms |
KR1020250011922A ADC-TRA41C
Click to Show/Hide
|
|||||
| Organization |
BYONDIS B.V.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Tratuzumab (P41C)
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.016 ug/ml | Positive HER2 expression (HER2+++/++) | ||
| Method Description |
ADCs were tested in HER2-positive SK-BR-3 cells and incubated for 6 days, then IC50 waa determined with CTG.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||